www.fdanews.com/articles/184182-pediatric-tourette-treatment-receives-orphan-drug-designation
Pediatric Tourette Treatment Receives Orphan-Drug Designation
October 31, 2017
The FDA granted orphan-drug status to Neurocrine Biosciences’ Ingrezza (valbenazine) for the treatment of children with Tourette syndrome.
The syndrome appears at age 6 on average and peaks in intensity at age 10.
Ingrezza was approved in February to treat adults with tardive dyskinesia, a condition typically characterized by involuntary grimacing, sticking out the tongue and sucking or fish-like movements of the mouth. The condition is associated with long-term treatment by antipsychotic medications.